InsiderTrades.com logo
Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners
From Colonial Metals   |   Ad
The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…
Claim your FREE 2024 Gold Guide
Philip Ashman net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Philip Ashman Biography and Net Worth

COO of Alimera Sciences
Dr. Philip Ashman Ph.D. serves as Chief Operating Officer, Senior Vice President - Commercial Operations Europe of the Company. He has served as Chief Operating Officer and Senior Vice President Commercial Operations Europe since January 2019. Previously, Dr. Ashman served as the Senior Vice President, Managing Director Europe since January 2013. Prior to joining us, Dr. Ashman held a number of leadership roles at Bayer from 2006 to 2012, including being responsible for leadership of the market access strategy in the U.K. for Bayer, covering all therapy areas including ophthalmology. Prior to this, Dr. Ashman served as Vice President Global Marketing Oncology at Bayer and also as Vice President Regional Business Unit Head (Europe) Oncology, responsible for the delivery of oncology sales and profitability targets in Europe, Canada, the Middle East and Africa. Before 2006, Dr. Ashman held UK-based business leadership positions in AstraZeneca and Sanofi. Dr. Ashman holds a doctorate in biochemistry from the University of London: Royal Holloway and Bedford, U.K., and a Bachelor of Science degree in biochemistry from the University College London, U.K.

What is Philip Ashman's net worth?

The estimated net worth of Philip Ashman is at least $107,359.66 as of April 8th, 2021. Dr. Ashman owns 19,379 shares of Alimera Sciences stock worth more than $107,360 as of November 21st. This net worth estimate does not reflect any other assets that Dr. Ashman may own. Additionally, Dr. Ashman receives a salary of $516,980.00 as COO at Alimera Sciences. Learn More about Philip Ashman's net worth.

How old is Philip Ashman?

Dr. Ashman is currently 59 years old. There are 5 older executives and no younger executives at Alimera Sciences. The oldest executive at Alimera Sciences is Mr. David R. Holland, Co-Founder, Chief Marketing Officer and Senior VP of Corporate Communications & Managed Markets, who is 60 years old. Learn More on Philip Ashman's age.

What is Philip Ashman's salary?

As the COO of Alimera Sciences, Inc., Dr. Ashman earns $516,980.00 per year. The highest earning executive at Alimera Sciences is Mr. Richard S. Eiswirth Jr., CEO & Director, who commands a salary of $949,270.00 per year. Learn More on Philip Ashman's salary.

How do I contact Philip Ashman?

The corporate mailing address for Dr. Ashman and other Alimera Sciences executives is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. Alimera Sciences can also be reached via phone at (678) 990-5740 and via email at [email protected]. Learn More on Philip Ashman's contact information.

Has Philip Ashman been buying or selling shares of Alimera Sciences?

Philip Ashman has not been actively trading shares of Alimera Sciences in the last ninety days. Most recently, Philip Ashman sold 45 shares of the business's stock in a transaction on Thursday, April 8th. The shares were sold at an average price of $9.62, for a transaction totalling $432.90. Following the completion of the sale, the chief operating officer now directly owns 19,379 shares of the company's stock, valued at $186,425.98. Learn More on Philip Ashman's trading history.

Who are Alimera Sciences' active insiders?

Alimera Sciences' insider roster includes Philip Ashman (COO), Richard Eiswirth, Jr. (CEO), John Jones (CFO), and James Largent (Director). Learn More on Alimera Sciences' active insiders.

Philip Ashman Insider Trading History at Alimera Sciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/8/2021Sell45$9.62$432.9019,379View SEC Filing Icon  
1/19/2018Sell25,500$1.20$30,600.0012,750View SEC Filing Icon  
1/17/2018Sell25,500$1.23$31,365.0038,250View SEC Filing Icon  
See Full Table

Philip Ashman Buying and Selling Activity at Alimera Sciences

This chart shows Philip Ashman's buying and selling at Alimera Sciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Alimera Sciences Company Overview

Alimera Sciences logo
Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
Read More

Today's Range

Now: $5.54
Low: $5.54
High: $5.54

50 Day Range

MA: $5.55
Low: $5.19
High: $5.60

2 Week Range

Now: $5.54
Low: $2.61
High: $5.65

Volume

N/A

Average Volume

376,318 shs

Market Capitalization

$290.24 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.25
JD Vance Predicts: Wall Street vs. Trump & Your Money
From Priority Gold   |   Ad
Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.
Get your free guide NOW before it's too late.